Aug 9, 2017
|
Ardelyx Focuses Resources on Late-Stage Programs and Reports Second Quarter 2017 Operational Results
|
Aug 2, 2017
|
Ardelyx Announces Date of Second Quarter Financial Results and Presentation at Wedbush PacGrow Healthcare Conference
|
May 12, 2017
|
Ardelyx Reports Successful Phase 3 T3MPO-1 Trial of Tenapanor in Patients with IBS-C
|
May 5, 2017
|
Ardelyx Reports First Quarter 2017 Operating Results and Highlights Recent Progress
|
Apr 18, 2017
|
Ardelyx To Present at Upcoming Spring Medical Meetings
|
Feb 27, 2017
|
Ardelyx Announces Presentation at Cowen and Company 37th Annual Healthcare Conference
|
Feb 17, 2017
|
Ardelyx Reports Clinical Progress and Fourth Quarter and Full Year 2016 Financial Results
|
Feb 15, 2017
|
Ardelyx Announces Successful Phase 3 Trial of Tenapanor for Hyperphosphatemia in Patients with End-Stage Renal Disease
|
Jan 3, 2017
|
Ardelyx Announces Initiation of Two Clinical Trials for RDX7675 for Treatment of Hyperkalemia
|
Jan 3, 2017
|
Ardelyx Announces Presentation at J.P. Morgan 35th Annual Healthcare Conference
|